Jet Bio-Filtration(SH:688026) Xin Lang Cai Jing·2025-09-01 02:20Core Insights - Jiet Bio (688026.SH) reported a total revenue of 268 million yuan for the first half of 2025, an increase of 31.89 million yuan compared to the same period last year, marking a year-on-year growth of 13.50% [1] - The net profit attributable to shareholders reached 46.34 million yuan, up by 16.34 million yuan year-on-year, reflecting a significant increase of 54.46% [1] - The net cash inflow from operating activities was 84.17 million yuan, ranking 44th among disclosed peers, with a year-on-year increase of 68.70 million yuan, representing a growth of 444.19% [1] Financial Metrics - The latest debt-to-asset ratio stands at 28.74%, a decrease of 0.02 percentage points from the previous quarter and a reduction of 0.10 percentage points year-on-year [3] - The gross profit margin is reported at 42.57%, an increase of 4.92 percentage points compared to the same period last year, achieving two consecutive years of growth [3] - The return on equity (ROE) is 3.78%, ranking 47th among disclosed peers, with an increase of 1.18 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.34 yuan, ranking 44th among disclosed peers, with an increase of 0.11 yuan year-on-year, reflecting a growth of 47.83% [3] - The total asset turnover ratio is 0.16 times, an increase of 0.01 times year-on-year, achieving two consecutive years of growth with a year-on-year increase of 7.43% [3] - The inventory turnover ratio is 1.21 times, ranking 48th among disclosed peers [3] Shareholder Structure - The number of shareholders is 7,848, with the top ten shareholders holding a total of 70.39 million shares, accounting for 50.15% of the total share capital [3] - The largest shareholder, Yuan Jianhua, holds 29.26% of the shares [3] - Other notable shareholders include JET(H.K.) BIOSCIENCE CO., LIMITED with 12.50% and Luoyang McKinnon Enterprise Management Partnership with 1.70% [3]